Hustler Words – In a quiet corner of Mill Valley, amidst the unassuming charm of a local bakery, Michael Polansky, a figure often associated with global celebrity, is pioneering a scientific endeavor that could redefine drug and cosmetic discovery. Far from the glitz of his public life as Stefani Germanotta’s (Lady Gaga) partner, Polansky is the visionary behind Outer Biosciences, a groundbreaking AI and biology startup training advanced models on living human skin tissue – a feat previously deemed impractical.
Polansky, whose demeanor mirrors that of a thoughtful academic despite his formidable resume, is leading a venture that has spent years perfecting the art of sustaining human tissue outside the body for over a month. This remarkable achievement addresses a critical bottleneck in biological research: the ethical and practical limitations of experimenting directly on humans and the inadequacy of traditional proxies like animal models or simplified cell cultures.
Outer Biosciences’ innovative methodology involves ethically sourcing human skin, primarily from plastic surgery procedures, which would otherwise be discarded. This tissue is acquired through vetted non-profit and commercial biobanks, adhering strictly to institutional review board oversight and documented donor consent. Crucially, samples arrive de-identified, ensuring donor privacy. A proprietary support system then meticulously nourishes the tissue and removes metabolic waste, extending its viability far beyond the industry standard of mere days. This extended lifespan allows researchers to observe slow biological processes like collagen remodeling, pigmentation changes, or barrier repair – phenomena that unfold over weeks, not days. For instance, the team can induce UVB damage and then track the subsequent stress, inflammation, and recovery responses over several weeks, gathering invaluable data.
Related Post
The true genius of Outer Biosciences lies in its integrated, self-enforcing AI system. Data from these living tissue experiments, whether validating or refuting initial hypotheses, is fed back into an AI model. This model then predicts which untested chemicals are most likely to yield beneficial effects on specific skin functions. What began as a laborious "brute force" approach, yielding a few leads over 18 months, has been dramatically accelerated by AI, now generating a new candidate compound approximately every six weeks. With six active leads and dozens of "hits" already logged, the pace of discovery is unprecedented in a field where only about 200 active ingredients (including FDA-approved drugs and research-backed cosmetics) are currently recognized.
Polansky’s journey to this scientific frontier is as intriguing as his current work. A Harvard alumnus in applied mathematics and computer science, he honed his analytical skills at Bridgewater Associates before transitioning to Silicon Valley. His path converged with tech titan Sean Parker, leading to roles at Founders Fund and later running Parker’s family office, where he managed investments and philanthropic initiatives, including the Parker Institute for Cancer Immunotherapy. It was through his philanthropic work that he met Cynthia Germanotta, Lady Gaga’s mother, who famously played matchmaker.
His partnership with Stefani Germanotta extends beyond the personal. She sits on the board of Outer Biosciences, and their ventures, including Gaga’s thriving cosmetics brand Haus Labs, find synergistic opportunities. Outer Biosciences’ chief scientist, Kyung-Jin Jang, serves on Haus Labs’ scientific advisory board, and joint projects have already been undertaken, underscoring Germanotta’s often-unseen business acumen.
Outer Biosciences is currently focused on discovering cosmetic ingredients, bypassing the lengthy FDA approval process required for drugs. Instead, the path involves securing a standardized industry name and undergoing safety testing under OECD guidelines, ensuring international acceptance. The company plans to license or sell these finished ingredients to beauty or pharmaceutical firms, allowing them to formulate and market products under their own brands. Four of the current six leads are already showing strong commercialization potential. Furthermore, Outer Biosciences generates revenue through collaborative research partnerships, including a pharmaceutical company investigating drug-induced skin rashes and beauty brands validating product development data.
Having raised approximately $23 million from early backers like Calm Capital, Brighter Capital, and Polansky’s own Hawktail, Outer Biosciences operates with a lean team of 19, mostly based outside Cambridge, Massachusetts. Polansky’s decision to finally speak publicly about the company after years of stealth operation stems from the growing confidence in their accumulated data.
While competitors like Vivodyne are also leveraging lab-grown organ tissue and AI, Outer Biosciences distinguishes itself through its use of real human tissue and the unique, proprietary data it generates. Unlike AI companies that scrape vast online datasets, Outer Biosciences is building a "biology internet" from scratch, a slower but more defensible approach. Notably, all of the company’s AI operations run on-premise, prioritizing data security over cloud convenience.
Polansky envisions a future where an accurate predictive model can pinpoint promising directions in skin biology without needing to physically run every experiment, dramatically accelerating discovery in dermatology. For now, the focus remains on refining the process of turning promising compounds into tangible products, with plans to expand the product development team. As Polansky aptly puts it, "It’s going to be fun to have people know that this is what we’ve been doing."
Leave a Comment